New results presented at the 2020 ASCO annual meeting show that patients with advanced or metastatic (spreading) cutaneous squamous-cell carcinoma (CSCC) who received the PD-1 inhibitor Libtayo (cemiplimab) lived much longer than patients who did not receive this PD-1 inhibitor.
This article reviews the promising findings presented at the 2020 ASCO meeting showing that treatment with the immunotherapy Libtayo may reduce pain and improve survival without disease progression in patients with advanced cutaneous squamous-cell carcinoma, or skin cancer.
Cutaneous squamous-cell carcinoma (CSCC), or skin cancer, is the second most common cancer in the United States. This article examines the results of a recent study on the first and only immunotherapy approved for patients with advanced or metastatic CSCC.
Last modified: July 17, 2020
Subscribe to CONQUER™: the patient voice™ magazine
Receive timely cancer news & updates, patient stories, and more.